1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Physician Views: Anti-CGRP mAbs looking to shake up migraine prevention – how and where will they fit in?

Physician Views: Anti-CGRP mAbs looking to shake up migraine prevention – how and where will they fit in?

  • May 2015
  • ID: 3090964
  • Format: PDF
  • By Firstword Pharma


Drugmakers may finally have cracked the code to developing safe and effective inhibitors of the calcitonin gene-related peptide (CGRP), a neuropeptide long believed to be associated with migraine headaches but which had proven exceedingly difficult to target with pharmaceuticals.

As it turns out, the key was moving on from small molecules, where companies like Boehringer Ingelheim and Merck & Co. ran into problems with off-target liver toxicities, and taking advantage of the highly specific nature of monoclonal antibodies. Four companies – Alder, Amgen, Eli Lilly and Teva – have recently reported Phase II results for mAbs candidates that are so far living up to the hype. (See ViewPoints: New data suggest the anti-CGRP race is closer than once thought.)

Cross-study comparisons of the products are fraught with difficulties given the highly variable and important differences in baseline characteristics, but Morgan Stanley analyst Matthew Harrison said that “in general, the placebo-adjusted responses are comparable across agents with an one-day reduction in mean migraine days and a roughly 10-percent to 25-percent increase in 50-percent responder rate.”

The most obvious differentiator among the four programmes is their target as Alder, Eli Lilly and Teva are developing mAbs that hit the CGRP ligand while Amgen’s AMG 334 binds directly to the CGRP receptor. Bernstein analyst Geoff Porges notes Amgen has floated the possibility that its approach may offer certain efficacy and/or dosing advantages over ligand-directed products, however, these have yet to emerge.

In fact, the opposite may turn out to be true when it comes to dosing as AMG 334’s short half-life (potentially a result of targeting of the CGRP receptor directly) may put it at a disadvantage to other products on dosing, particularly Alder’s ALD403, which has a half-life of 26 days and is expected to be dosed quarterly. AMG 334’s half-life is estimated at only 11 days, meaning it is likely to require monthly dosing. Eli Lilly’s LY2951742 and Teva’s TEV-48125 are testing monthly dosing schedules as well at the moment. Dosing is not a clear victory for Alder, however, as its ALD403 is only available – for the time being anyway – for intravenous delivery, whereas the other three agents can be self-administered subcutaneously.

Unlike its three competitors, which have only reported data in patients with episodic migraines, Teva’s TEV-48125 is the only agent that has generated data in the all-important chronic migraine setting, a distinction that Porges said could give the Israeli drugmaker a potential leg up. (See ViewPoints: Handicapping the four-horse race among anti-CGRP mAbs for migraine.)

Patients, physicians, payers and investors will be watching the progress being made with anti-CGRP mAbs closely as there is a clear unmet need for safe and effective prophylactic therapies for high-frequency episodic and chronic migraines, which is a market that Cowen analyst Eric Schmidt believes could represent a multi-billion dollar opportunity for products that pass regulatory muster. And no wonder given estimate from the US Centers for Disease Control that more than 14 percent of adults have experienced a migraine or severe headache in the past three months.

Preventative therapy for patients with episodic migraines involves some combination of antihypertensives, antiepileptics and antidepressants, often supplemented by acute rescue medications like triptans. Recently, Botox (botulinum toxin A) from Actavis became the first FDA-approved prophylactic product for chronic migraines and, while it is not indicated for episodic migraines, it has become the go-to agent in this setting for many doctors, according to UBS analyst Marc Goodman. Also in the mix is STX-Med’s Cefaly, a transcutaneous electrical nerve stimulation (TENS) device that last year became the first device to be approved in the US for migraines.

Given the complex treatment environment into which the anti-CGRP mAbs are heading towards, characterised by the large unmet need and highly variable nature of the management and responses from patients with episodic or chronic migraines, FirstWord PLUS commissioned a poll of neurologists and primary care physicians in the US and EU5. To gain a better understanding of how they see the new class of migraine prophylactic fitting in, as well as what factors might help set individual products apart from the rest, the questions they are being asked include…

What drug(s) do you tend to prescribe for the prevention of high-frequency episodic migraines (defined as fewer than 15 migraine days per month)?
In patients with (high-frequency) episodic migraines, preliminary Phase II data for several anti-CGRP mAbs showed roughly a 1-day reduction in mean migraine days per month and 10% to 25% improvement in 50%-responder rates. If anti-CGRP mAbs are eventually approved based on similar data, which would you be more likely to prescribe first to prevent episodic migraines?
In patients with chronic migraines (defined as more than 15 migraine days per month), preliminary Phase II data for one anti-CGRP mAb showed 50%-responder rates of greater than 50%, rapid onset and lower consumption of acute migraine medications. If this product and/or others from the CGRP class are approved based on similar data, which would you be more likely to prescribe first to prevent chronic migraines?
If multiple anti-CGRP mAbs are approved at roughly the same time based on comparable safety and efficacy data, what other factors will be most important when you decide which drug to prescribe?
For patients with moderate to severe migraines, would you be more likely to prescribe a subcutaneous drug that is dosed monthly or an intravenous drug that is dosed quarterly?

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2019

Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2019

  • $ 2000
  • August 2019

Microscopic Polyangiitis (MPA) - Pipeline Review, H2 2019SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Microscopic Polyangiitis (MPA) - Pipeline Review, H2 ...

Integrin Alpha 4 - Pipeline Review, H2 2019

Integrin Alpha 4 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Integrin Alpha 4 - Pipeline Review, H2 2019SummaryIntegrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) pipeline Target constitutes close to 16 molecules. The latest ...

Toll Like Receptor 4 - Pipeline Review, H2 2019

Toll Like Receptor 4 - Pipeline Review, H2 2019

  • $ 3500
  • August 2019

Toll Like Receptor 4 - Pipeline Review, H2 2019SummaryToll Like Receptor 4 (hToll or CD284 or TLR4) - Toll-like receptor 4 is a protein encoded by the TLR4 gene. This receptor is mostly expressed in placenta, ...

Download Unlimited Documents from Trusted Public Sources

Therapy Market in Australia

  • November 2019
    122 pages
  • Therapy  



  • Australia  

    United Kingdom  


View report >

Opioid Market in the US

  • November 2019
    56 pages
  • Opioid  

  • United States  

    North America  

View report >

Hospital Industry in the US

  • November 2019
    44 pages
  • Hospital  



  • United States  

View report >

Country Reports

United States


Reportlinker.com © Copyright 2019. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on